";s:4:"text";s:5478:"Draft Guidance on Imatinib Mesylate Recommended Apr 2013; Revised Jul 2014 This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. If this is the first time you are logging in on the new site, you will need to Updated September 2020.The last exam window of 2020 is currently open. RAPS Convergence is going virtual. One of our most valuable contributions to the profession is the Regulatory Code of Ethics. Check out the Member Knowledge Center for free webcasts, publications and online courses.Like all professions, regulatory is based on a shared set of competencies. Tab In addition to the provided information, sponsors and investigators of any Investigational New Drug (IND)-exempt pharmacokinetic (PK) studies, pharmacodynamic (PD) studies, or bioequivalence (BE) and/or bioavailability (BA) studies involving human subjects in support of an ANDA should refer to the current RLD labeling, including BOXED WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS sections. The site navigation utilizes arrow, enter, escape, and space bar key commands. On July 11, 2018, the U.S. Food and Drug Administration (FDA or the Agency) made available a suite of six scientific draft guidance documents on human gene therapy (GT) products. Life Sciences . The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.Your membership opens the door to free learning resources on demand. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. The most recently published guidances (new and revised) are listed below. GT products are products that mediate their effects by transcription or translation of transferred genetic material, or by specifically altering host (human) genetic sequences. Recommended Nov 2009; Revised Oct 2016, Oct 2018, Nov 2019 . This draft guidance, when finalized, will represent the current thinking of th e Food and Drug Administration (FDA, or the Agency) on this topic. Resources, news and special offers to support you and your professional development during this difficult time. Join the brightest minds in regulatory online to gain the latest knowledge in the field in an all-virtual experience with workshops, one-on-one expert sessions, and networking communities.This year, our European regulatory community will converge online with a fully virtual program that will allow attendees to experience Euro Convergence live online from the safety and comfort of their homes.RAPS' “how to” guide to developing a comprehensive global regulatory strategy for all types of medical devices. Your membership opens the door to free learning resources on demand. Resources, news and special offers to support you and your professional development during this difficult time. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals. To successfully develop and manufacture a generic drug product, an applicant should consider that their product is expected to be: pharmaceutically equivalent to its reference listed drug (RLD), i.e., to have the same active ingredient, dosage form, strength, and route of administration under the same conditions of use; bioequivalent to the RLD, i.e., to show no significant difference in the rate and extent of absorption of the active pharmaceutical ingredient; and, consequently, therapeutically equivalent, i.e., to be substitutable for the RLD with the expectation that the generic product will have the same safety and efficacy as its reference listed drug.According to 21 CFR 320.24, different types of evidence may be used to establish bioequivalence for pharmaceutically equivalent drug products, including in vivo or in vitro testing, or both. Enter and space open menus and escape closes them as well. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels. menus and toggle through sub tier links. Updated September 2020. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. This year, our European regulatory community will converge online with a fully virtual program that will allow attendees to experience Euro Convergence live online from the safety and comfort of their homes. Register by 8 October to take the RAC exam this autumn.